Research programme: sulphostin - Nippon Kayaku
Latest Information Update: 22 Feb 2010
At a glance
- Originator Nippon Kayaku
- Mechanism of Action CD26 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 23 Nov 2005 Preclinical trials in Undefined in Japan (unspecified route)